Hepatitis C Information Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatments here at Hepatitis-Central.com.

Hep C information
Free Newsletter
Hepatitis C Newsletter
We value your privacy. We will not rent your email to anyone.
HEPATITIS NEWS
The top stories compiled from over 5,500 sources, updated every 15 minutes

Hepatitis E confirmed in Gulu
Gulu Hepatitis E has been confirmed in Odeke Sub-county in Gulu District. The District Health Educator Mr Okot Lukaki said three cases have been reported. He said a task force has been created to ensure cleanliness especially in the camps. Mr Lukaki said

New hepatitis C virus vaccines study findings reported from Research Center for Infectious Diseases
- (NewsRx.com) -- Fresh data on hepatitis C virus are presented in the report 'Open-label trial of therapeutic immunization with oral V-5 Immunitor (V5) vaccine in patients with chronic hepatitis C.' According to recent research published in the journal

Hepatitis E Risk 'On the Rise'
(UN Integrated Regional Information Networks/All Africa Global Media via COMTEX News Network) -- More people are at risk of contracting the Hepatitis E virus (HEV) in the northern Uganda district of Kitgum, according to a surveillance health report. 'The

UPDATES AND COMMENTARY RSS Feed

Good News for Non-Responders to HCV Combination Therapy
A Phase 3 trial evaluating ZADAXIN® (thymalfasin) as a potential third component for Hepatitis C traditional combination therapy has just been completed. Although the data is currently being analyzed and won't be available until later in the year, the lead...

Purer, Less Costly Interferon for Hepatitis C and B Treatment
The Taiwan-based biopharmaceutical company PharmaEssentia Corp. is testing P1101, its third-generation PEG-interferon-alpha drug candidate. Because it is a longer-lasting, purer interferon that is less costly to produce, P1101 could enhance the treatment options for Hepatitis C and B....

New Technology May Help Treat Hepatitis
While pharmaceutical companies are racing to find safer, more effective treatments for viral Hepatitis C and B, physicists from Arizona have a unique perspective on accomplishing the same goal. Learn how these scientists believe the virus could be rendered harmelss...



Relationship of the Genomic Complexity of Hepatitis C Virus With Liver Disease Severity and Response to Interferon in Patients With Chronic HCV Genotype 1b Infection

table  2.   Basal Features and Complexity of the HVR1, as Determined by SSCP Analysis, in Patients With Genotype 1b HCV Chronic Infection According to the Response to a Course of Interferon Therapy

Sustained
Response
(n = 12)
Transient
Response
(n = 41)
No
Response
(n = 69)

Age (years) 41.1 ± 13.0 46.4 ± 11.7 48.8 ± 11.4
Sex (M/F) 7/5 22/19 44/25
Source of infection
  Blood transfusion 4 (33.3%) 11 (26.8%) 22 (31.9%)
  I.V. drug abuse 3 (25%)   2 (4.9%) 4 (5.8%)
  Unknown 5 (41.7%) 28 (68.3%) 43 (62.3%)
AST (IU/L) 87.8 ± 60.8 80.0 ± 52.5 109.1 ± 69.3
ALT (IU/L) 190.6 ± 138.1 142.6 ± 85.8 166.5 ± 114.6
HCV-RNA (copies × 103/mL) 25 ± 35* 346 ± 388 415 ± 506
Number of SSCP bands 7.5 ± 3.9 8.3 ± 2.9 8.2 ± 3.6
High complexity of quasispecies 4 (33.3%) 16 (39%)   26 (37.6%)
Low complexity of quasispecies 8 (66.7%) 25 (61%)   43 (62.4%)

NOTE. Quantitative data are expressed as means ± SD. Numbers in parenthesis represent percentages. Complexity of quasispecies was defined as low (8 bands or less) or high (more than 8 bands), according to the median value of the number of bands in the SSCP analysis.
* Significantly different (P = .04) from transient responders and nonresponders by ANOVA.

Return To Article

Copyright © 1999 by the American Association for the Study of Liver Diseases.

  Hep C information

Information at this website is for educational purposes only; statements about products and health conditions
have not been evaluated by the U.S. Food & Drug Administration.

©1994-2008 Hepatitis-Central.com
Updated 04 Jul 2008